title: Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.
abstract: BACKGROUND
  In 2001, the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program established Residual Tissue Repositories (RTR) in the Hawaii, Iowa, and Los Angeles Tumor Registries to collect discarded tissue blocks from pathologic laboratories within their catchment areas. To validate the utility of the RTR for supplementing SEER's central database, we assessed human epidermal growth factor receptor-2 (HER2) and estrogen receptor expression (ER) in a demonstration project.
  
  
  METHODS
  Using a prepared set of tissue microarrays (TMAs) residing in the Hawaii Tumor Registry (HTR), we performed standard immunohistochemistry. Breast cancers in the TMA were diagnosed in 1995, followed through 2006, and linked to SEER's main database.
  
  
  RESULTS
  The TMA included 354 cases, representing 51% of 687 breast cancers in the HTR (1995). The HTR and TMA cases were similar with respect to patient demographics and tumor characteristics. Seventy-six percent (76%, 268 of 354) of TMA cases were HER2+ and/or ER+, i.e., 28 HER2+ER-, 12 HER2+ER+, and 228 HER2-ER+. There were 67 HER2-ER- cases and 19 were unclassified. Age distributions at diagnosis were bimodal with dominant early-onset modes for HER2+ER- tumors and dominant late-onset modes for HER2-ER+ breast cancers. Epidemiologic patterns for concordant HER2+ER+ (double-positive) and HER2-ER- (double-negative) were intermediate to discordant HER2+ER- and HER2-ER+.
  
  
  CONCLUSIONS
  Results showed contrasting incidence patterns for HER2+ (HER2+ER-) and ER+ (HER2-ER+) breast cancers, diagnosed in 1995. Though sample sizes were small, this demonstration project validates the potential utility of the RTR for supplementing the SEER program.
authors.affiliation: NIH/NCI/DCEG, EPS Room 8036, 6120 Executive Blvd, Bethesda, MD 20852, USA. wanderso@mail.nih.gov
authors.forename: W F
authors.initials: WF
authors.lastname: Anderson
authors.forename: S
authors.initials: S
authors.lastname: Luo
authors.forename: N
authors.initials: N
authors.lastname: Chatterjee
authors.forename: P S
authors.initials: PS
authors.lastname: Rosenberg
authors.forename: R K
authors.initials: RK
authors.lastname: Matsuno
authors.forename: M T
authors.initials: MT
authors.lastname: Goodman
authors.forename: B Y
authors.initials: BY
authors.lastname: Hernandez
authors.forename: M
authors.initials: M
authors.lastname: Reichman
authors.forename: M P
authors.initials: MP
authors.lastname: Dolled-Filhart
authors.forename: R M
authors.initials: RM
authors.lastname: O'Regan
authors.forename: M
authors.initials: M
authors.lastname: Garcia-Closas
authors.forename: C M
authors.initials: CM
authors.lastname: Perou
authors.forename: I
authors.initials: I
authors.lastname: Jatoi
authors.forename: R W
authors.initials: RW
authors.lastname: Cartun
authors.forename: M E
authors.initials: ME
authors.lastname: Sherman
mesh_terms: D017677:Age Distribution; D017668:Age of Onset; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D015994:Incidence; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D011960:Receptors, Estrogen / Q000235:genetics*; D011980:Receptors, Progesterone / Q000032:analysis; D012042:Registries; D015203:Reproducibility of Results; D018426:SEER Program
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C508053:ERBB2 protein, human